TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Parameters 3 Months, 9 Months, and 2 Years After Bariatric Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subjects in this study will represent both male and female patients with clinically severe obesity (BMI \> 40kg/m2 or 35kg/m2 with significant obesity related co-morbidities), who have chosen to undergo elective bariatric surgery. Patients are screened through the University of Texas Houston Bariatric Surgery Center (UTHBSC) and are evaluated for bariatric surgery, defined in this study as small pouch gastric bypass with Roux-en-Y (SPGB), or laparoscopic adjustable gastric banding (LAGB). Adults (\>18)from diverse ethnic backgrounds, with clinically severe obesity, are eligible to be evaluated for bariatric weight loss surgery in the UTHBSC. Candidates considered for the study are patients who not only fulfill the criteria for weight loss surgery, but also demonstrate a high likelihood of complying with the long-term follow-up that is required for a successful study.~Patients who have components of the metabolic syndrome (hypertension, diabetes, and dyslipidemia) will be included if these complications do not preclude a safe operation. .~Exclusion Criteria: Exclusion criteria include age over 70 years, current history of smoking, coronary artery disease, congestive heart failure, ischemic cardiomyopathy, known peripheral vascular disease, severe psychiatric disease, any medical problem or physical contraindication for surgery (as determined by the physician) and pregnancy. This study will be limited to adults since the safety of gastric bypass surgery has not been shown to be safe in children in large clinical trials~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Bariatric Surgery (Type: None): Procedures were not part of the trial. Patients already undergoing these clinical procedures agreed to analysis and follow-up for research purposes. All patients had one of two different types of procedures, but outcome analyses did not distinguish between the two procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Clinical diagnosis of multifocal motor neuropathy, supported by electrophysiological findings~Exclusion Criteria:~* Other severe medical conditions~* Pregnancy and lactation~* Anti-coagulation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Subcutaneous Ig given twice a week.
- 2 (Type: ACTIVE_COMPARATOR): Intravenous Ig

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of ATL-962 in Obese Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type II diabetes~* Body mass index 28-45kg/m2~* HbA1c 6%-10%~Exclusion Criteria:~* Significant weight loss in the previous 3 months~* Weight gain during the run-in period~* Other serious systemic conditions, except controlled hypertension, mild asthma, and primary hypothyroidism~* History of GI disorders~* Previous surgery for weight loss

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~For Patient:~* Older than 2 years of age and between 6 and 136 kg body weight~* Recipient of clinical diagnosis of epilepsy, taking a stable antiepileptic drug regimen for at least 2 weeks, and requiring intermittent medical intervention to control episodes of acute repetitive seizures (ARS)~* Experienced at least 2 episodes of ARS in previous year, one of which occurred in previous 6 months~* Has episodes of ARS that include complex partial or generalized seizures~* Has a responsible caregiver available to participate~* Is not pregnant or lactating and is practicing an acceptable method of birth control.~For Caregiver:~* Age of 18 years or older and has demonstrated responsibility as a caregiver through training to:~  * Recognize an episode of repetitive seizures for which the injection was intended,~ * Administer study drug~ * Count and record seizures and respiratory rate in the patient diary,~ * Monitor the patient and record observations in the patient diary for 12 hours following study drug treatment~ * Recognize the need for immediate medical attention.~Key Exclusion Criteria~For Patient:~* Petit mal status or petit mal variant status~* History of ARS consistently progressing to status epilepticus~* History of failure to respond to benzodiazepine treatment~* Hypersensitivity to diazepam~* Acute narrow angle glaucoma~* Alcohol and/or other substance abuse~* Has taken another investigational drug in previous 30 days~* Acute or progressive neurologic or severe psychiatric disease or severe mental abnormality.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): During the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS).
- Diazepam (Type: EXPERIMENTAL): During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) ≥ 50~* Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer~* Prior chemotherapy is permitted with no limit on the number of prior regimens~* Two weeks or more have elapsed since last chemotherapy or radiation treatment~* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2~* Is female, ≥ 18 yrs of age~* Protocol defined appropriate laboratory values~* Negative pregnancy test within 7 calendar days prior to registration~* Has signed a patient informed consent~Exclusion Criteria:~* Had prior treatment with ixabepilone or other epothilones~* Has HER2+ disease~* Has a known, prior, severe (National Cancer Institute Common Terminology Criteria Adverse Events \[NCI CTCAE\] Grade 3-4) history of hypersensitivity reaction to a drug formulated in Cremophor ® EL (polyoxyethylated castor oil)~* Is receiving concurrent immunotherapy, hormonal therapy or radiation therapy~* Is receiving concurrent investigational therapy or has received such therapy within the past 30 days~* Has peripheral neuropathy \> Grade 1~* Has evidence of central nervous system (CNS) involvement requiring radiation or steroid treatment. Participants with stable brain metastases who are off steroids at least 2 weeks are eligible~* Is pregnant or breast feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): ixabepilone 16 mg/m\^2 weekly for 3 weeks followed by 1 week rest
- Arm 2 (Type: ACTIVE_COMPARATOR): ixabepilone 40 mg/m\^2 every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The SIM-SOF Trial for Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic hepatitis c,~* cirrhosis biopsy-proven, or via fibrotest,~* CPT score less than 7,~* genotype 1a,~* INR 2.3 or less,~* serum albumin greater than 2.7 gm/dL,~* total bilirubin less than 3 gm/dL,~* platelet count 50,000 per cubic milliliter or more~* GFR \>50 ml/min~Exclusion Criteria:~* non genotype 1a,~* history of CPT class B or C or decompensation or history of same,~* HIV or HBV coinfection,~* prior treatment with boceprevir, telaprevir or any other direct acting antiviral agent,~* uncontrolled psychiatric or cardiopulmonary disorders,~* planning pregnancy or unwilling/unable to practice contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard (Type: ACTIVE_COMPARATOR): Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
- Simeprevir + Sofosbuvir (Type: EXPERIMENTAL): (SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 2-month-old infants (42 to 98 days)~* Available for the entire study period (14 months)~Exclusion Criteria:~* Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis, polio, or Hib vaccines~* A previous anaphylactic reaction to any vaccine or vaccine-related component.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 13vPnC
- 2 (Type: ACTIVE_COMPARATOR): 7vPnC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Stage I or II disease (T1-T2, N0, M0/MX disease)~    * No chest wall invasion by tumor (T3 disease)~* Medially or centrally located lesion~* No multicentric disease~  * Multifocal disease allowed~* No clinically positive axillary nodes~* No enlarged internal mammary nodes by CT scan~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Male or female~* Menopausal status not specified~* American Society of Anesthesiologists (ASA) physical status classification 1-2~* Not pregnant or nursing~* Negative pregnancy test~* No other concurrent known, invasive malignancy~* No known chronic pulmonary disease~* No known allergy to methylene blue or isosulfan blue~PRIOR CONCURRENT THERAPY:~* No prior thoracic or cardiac surgery~* No prior ipsilateral chest tube placement~  * Contralateral chest tube placement allowed~* No prior neoadjuvant chemotherapy~* No prior radiotherapy to the mediastinum

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Sentinel Lymph Node Biopsy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has completed the Week 24 visit procedures of Study FKB327-002 (NCT02260791) and are continuing with methotrexate~2. In the investigator's opinion, the patient showed a clinical response to treatment during Study FKB327-002 (NCT02260791)~Exclusion Criteria:~1. Patient has evidence of a serious adverse event (SAE) ongoing from Study FKB327-002~2. Patient has presence of active and/or untreated latent tuberculosis (TB)~Other Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FKB327 (Type: EXPERIMENTAL): Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
- Humira® (Type: ACTIVE_COMPARATOR): Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently being treated for ADHD~Exclusion Criteria:~* Other psychiatric diagnoses~* Significant cognitive impairment~* Chronic medical illnesses~* Structural cardiac defects~* Significant abnormal lab tests~* Taking disallowed medications~* Positive drug test

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- NT0102 (Type: EXPERIMENTAL): After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given 20-60 mg of NT0102 as oral disintegrating tablet (ODT) once daily for one week during the double-blind treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given placebo as matching ODT once daily for one week during the double-blind treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Efficacy After Umbilical Hernia Repair in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects ages \> 5 to \< 18 years.~2. American Society of Anesthesiology (ASA)physical status 1 or 2.~3. Patients who undergo an umbilical hernia repair at CHOP.~Exclusion Criteria:~1. Parents/patients refusal to the placement of a rectus sheath nerve block.~2. Subjects with allergy to bupivacaine.~3. Patients who are developmentally delayed which precludes their participation in pain scale reporting.~4. Parents who do not comprehend English sufficiently well to read the consent and ask questions.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 1) One group will receive the rectus sheath block prior to Umbilical hernia repair.
- 2 (Type: ACTIVE_COMPARATOR): 2) The second group will receive local anesthetic infiltration of the surgical site at the end the umbilical hernia repair.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is pre-menopausal female 18 to 51 years of age at Screening.~* Subject has diagnosis of uterine fibroids documented by a Pelvic Ultrasound.~* Subject has heavy uterine bleeding associated with uterine fibroids.~Exclusion Criteria:~* Subject has had a myomectomy, uterine artery embolization or high intensity focused ultrasound for fibroid destruction within 6 months prior to Screening or endometrial ablation within 5 years prior to Screening.~* Subject has a history of osteoporosis or other metabolic bone disease.~* Subject shows evidence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including depression, schizophrenia, bipolar disorder), or neurologic diseases or any uncontrolled medical illness such as uncontrolled type 2 diabetes. Subject has any history of attempted suicide.~* Subject has a history of clinically significant condition(s) including but not limited to: \* Symptomatic Endometriosis \* Epilepsy or seizures \* Type 1 diabetes \* Chronic kidney disease \* Any cancer (except treated basal cell carcinoma of the skin), including breast or ovarian cancer or subject has taken any systemic cancer chemotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Placebo (Type: PLACEBO_COMPARATOR): Placebo for elagolix and placebo for E2/NETA twice daily (BID)
- Cohort 1: Elagolix 300 mg BID (Type: EXPERIMENTAL): Elagolix 300 mg BID alone
- Cohort 1: Elagolix 300 mg BID plus LD E2/NETA QD (Type: EXPERIMENTAL): Elagolix 300 mg BID plus low-dose (LD) E2/NETA once daily (QD)
- Cohort 1: Elagolix 300 mg BID plus SD E2/NETA QD (Type: EXPERIMENTAL): Elagolix 300 mg BID plus standard-dose (SD) E2/NETA QD
- Cohort 2: Placebo (Type: PLACEBO_COMPARATOR): Placebo for elagolix and E2/NETA QD
- Cohort 2: Elagolix 600 mg QD (Type: EXPERIMENTAL): Elagolix 600 mg QD alone
- Cohort 2: Elagolix 600 mg QD plus LD E2/NETA QD (Type: EXPERIMENTAL): Elagolix 600 mg QD plus LD E2/NETA QD
- Cohort 2: Elagolix 600 mg QD plus SD E2/NETA QD (Type: EXPERIMENTAL): Elagolix 600 mg QD plus SD E2/NETA QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Using the Proteolytic Fraction P1G10 From V. Cundinamarcensis to Heal Diabetic Foot Ulcer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of diabetes 2 had~* Hemoglobin ≥ 9.0 g/dl~* total leukocytes ≥ 300/ mm3~* platelets ≥ 100.00/mm3~* total bilirubin ≤ 1.0 mg/dL~* aspartate aminotransferase between 14 and 17 U/L in males and 10 and 33 U/L in females~* pyruvate transaminase between 10 and 40 U/L in males and 7 and 35 U/L in females~* creatinine between 0.70 and 1.20 mg/dL in males and 0.6 and 1.0 mg/dL in females~Exclusion criteria~* pregnant females~* lactating mothers~* highly exuding ulcers~* patients receiving alternative treatments for ulcers~* reported allergy to the components included in the formulation,~* concomitant uncontrolled morbidity~* current active infections,~* HIV serum positives~* diagnosed with neoplasia or undergoing treatment with a cytostatic, or immunosuppressing agent~* individuals subjected to radiotherapy within the last 3 months before beginning the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydrogel treatment (Type: ACTIVE_COMPARATOR): It refers to the standard treatment currently applied for foot ulcers at the Health Center where the study was conducted. The intervention was applied to the cohort, three times a week during 16 weeks or when the wound attained full epithelization. The wound bed was cleaned with physiological serum before application of Hydrogel.
- P1G10 treatment (Type: EXPERIMENTAL): It refers to the experimental parallel intervention consisting of three weekly applications of 0.1% P1G10 dispersed in the hydrosoluble vehicle during a 16-week period, or until full epithelization of the wound. The wound bed was cleaned with physiological serum before application of the drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete